Introducing a New Insights-as-a-Service Solution for Faster, Smarter Decision-Making
SAN FRANCISCO, Sept. 30, 2015 (GLOBE NEWSWIRE) — Zephyr Health, the leading insights-as-a-service company today launched Zephyr Illuminate™, its next-generation enterprise solution for pharmaceutical, biotechnology, medical device and diagnostics companies. Zephyr Illuminate integrates global health data from thousands of disconnected sources to provide deep and actionable customer and market insights for faster, more confident decision-making across the entire product planning and launch lifecycle.
“More than 400 products will be launched in the next three years, and yet industry statistics tell us that fewer than half will achieve even half of their sales forecast. Why? Because information guiding these predictions was either wrong, incomplete or more importantly, not driven by the latest available information,” said William King, founder and CEO, Zephyr Health. “Illuminate solves long-standing issues of accessing and integrating data. This new product maximizes time to market for life sciences companies and provides market metrics to instrument their business with facts at every stage of product development, launch and commercialization.”
Illuminate brings together the core capabilities of Zephyr’s existing applications – Voyager, Cocktail and Kaleidescope – creating a next-generation insights platform with a sleek new Web and mobile interface for business users in headquarters and in the field. Illuminate’s Recommendations Engine uncovers new market and customer insights and delivers them to users via easy integration into CRM or Business Intelligence solutions. Proprietary algorithms link out-of-the-box public global healthcare data with customer and vendor data to deliver predictive analytics and actionable business insights.
“We’ve developed the world’s first all-in-one insights engine for global health data,” said Ronald Meaux, vice president of Products at Zephyr Health. “Powerful algorithms and intuitive applications make it easy for our customers to identify the best physicians and hospitals around the world for clinical research, market influence and sales potential.”
Zephyr Illuminate features include:
About Zephyr Health
Founded in 2011 by William King, Zephyr Health is the leading insights-as-a-service company harnessing the power of global health data to address critical business and patient needs. From clinical trials to market strategy and sales, Zephyr Illuminate™ helps Life Sciences companies – pharmaceutical, biotech, medical device and diagnostics – make confident decisions faster across the entire product lifecycle with precise and predictive customer and market insights. Zephyr Health’s customers include Fortune 100 biopharmaceutical, diagnostic and medical device companies Amgen, Genentech, Gilead, GSK, Medtronic, Onyx and Stryker.
Zephyr Health is a privately held company headquartered in San Francisco with offices in London, UK, and Pune, India. Zephyr Health is venture backed by Google Ventures, Kleiner Perkins Caufield & Byers and Icon Ventures. For more information, please visit: www.zephyrhealth.com.
Source: Zephyr Health
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”
